patients with cll on continuous ibrutinib have a life expectancy comparable to healthy individuals
Published 3 weeks ago • 62 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
1:05
long-term outcomes of patients with cll treated with continuous ibrutinib
-
1:14
overall survival benefit in elderly patients with cll treated with first-line ibrutinib
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
3:47
underrepresentation of elderly patients with cll in clinical trials
-
1:18
the impact of the approval of pirtobrutinib on the treatment landscape for patients with cll
-
4:33
calquence® (acalabrutinib) patient testimonials: marialice’s story
-
6:56
prognostic factors in acute lymphoblastic leukemia
-
13:20
a phase 3 study of biosimilar bi 695501 versus adalimumab in patients with crohn’s disease - vjbm
-
1:13
5-year follow-up of patients with cll treated in first-line with ibrutinib plus venetoclax
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
1:22
does acalabrutinib increase the risk of hypertension in patients with cll?
-
2:29
real-world comparison of ttnt with ibrutinib or acalabrutinib in cll
-
1:19
acalabrutinib vs ibrutinib in previously untreated high-risk cll
-
1:38
front-line use of ibrutinib for cll in a real-world setting
-
3:00
five-year follow-up of the captivate trial: ibrutinib retreatment in patients with cll
-
1:22
long-term outcomes and toxicities of ibrutinib in cll
-
4:29
first-line ibrutinib vs chemoimmunotherapy in cll: a real-world data analysis
-
2:00
population-based studies for ibrutinib in cll
-
1:31
maic of pirtobrutinib vs venetoclax continuous monotherapy in patients with r/r cll
-
1:20
health-related quality of life with zanubrutinib versus ibrutinib for patients with r/r cll
-
2:06
effects of dose adjustment of first-line ibrutinib on real-world dosing patterns and outcomes in cll
-
0:55
acalabrutinib in patients with cll and mcl undergoing allosct